Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.37 |
| ▸ | PRKCA | P17252 | 1/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4390284 | 0.90 | NPY5R (0.37) | KDM4EMEN1KMT2ANPSR1POLB | |
| SCHEMBL2156557 | 0.85 | PRKCA (0.39) | KDM4EKMT2ANPSR1SIGMAR1PRKCA | |
| SCHEMBL2156837 | 0.84 | KDM4E (0.34) | KDM4EKMT2ANPSR1POLBSIGMAR1 | |
| SCHEMBL3081040 | 0.82 | PRKCA (0.54) | KDM4EMEN1KMT2ANPSR1POLB | |
| SCHEMBL4390041 | 0.82 | ALDH1A1 (0.37) | KDM4EKMT2ANPSR1POLBSIGMAR1 | |
| SCHEMBL4387244 | 0.81 | PRKCA (0.35) | KDM4EKMT2ANPSR1PRKCAMMP12 | |
| SCHEMBL4389329 | 0.81 | SIGMAR1 (0.34) | KDM4EMEN1KMT2ANPSR1SIGMAR1 | |
| SCHEMBL4394890 | 0.80 | PRKCA (0.34) | KDM4EMEN1KMT2ANPSR1SIGMAR1 | |
| SCHEMBL4382196 | 0.80 | NOTUM (0.42) | KDM4EPOLBLMNA | |
| SCHEMBL2157700 | 0.79 | PRKCA (0.39) | KDM4EPOLBPRKCAMMP12NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105227-A1 | Thienopyrroles As Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-04-23 | — | — | US | claimed |
| US-7973026-B2 | Thienopyrroles as antiviral agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-07-05 | — | — | US | disclosed |
| US-20090105227-A1 | Thienopyrroles As Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105227-A1 | Thienopyrroles As Antiviral Agents | ZC3HAV1, HAVCR2, ZC3HAV1L | KDM4E 3275/4885MEN1 4599/4885KMT2A 3202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.